The 10-day moving average for BAX crossed bullishly above the 50-day moving average on October 22, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 9 of 13 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 69%.
The Momentum Indicator moved above the 0 level on September 30, 2026. You may want to consider a long position or call options on BAX as a result. In 48 of 85 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 56%.
The Moving Average Convergence Divergence (MACD) for BAX just turned positive on September 30, 2026. Looking at past instances where BAX's MACD turned positive, the stock continued to rise in 21 of 45 cases over the following month. The odds of a continued upward trend are 47%.
BAX moved above its 50-day moving average on October 22, 2026 date and that indicates a change from a downward trend to an upward trend.
Following a +4.65% 3-day Advance, the price is estimated to grow further. Considering data from situations where BAX advanced for three days, in 166 of 288 cases, the price rose further within the following month. The odds of a continued upward trend are 58%.
The Aroon Indicator entered an Uptrend today. In 143 of 210 cases where BAX Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 68%.
The 10-day RSI Indicator for BAX moved out of overbought territory on October 16, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 33 similar instances where the indicator moved out of overbought territory. In 18 of the 33 cases, the stock moved lower in the following days. This puts the odds of a move lower at 55%.
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 33 of 55 cases where BAX's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 60%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where BAX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 68%.
BAX broke above its upper Bollinger Band on October 15, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Tickeron Price Growth Rating for this company is 16 (best 1 - 100 worst), indicating outstanding price growth. BAX’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 56 (best 1 - 100 worst), pointing to average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 94 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Valuation Rating of 96 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.058) is normal, around the industry mean (4.961). P/E Ratio (-11.932) is within average values for comparable stocks, (37.232). BAX's Projected Growth (PEG Ratio) (36.677) is very high in comparison to the industry average of (4.143). Dividend Yield (0.002) settles around the average of (0.005) among similar stocks. P/S Ratio (1.057) is also within normal values, averaging (56.876).
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. BAX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.
PHG moved above its 50-day moving average on October 20, 2026 date and that indicates a change from a downward trend to an upward trend. In 30 of 44 similar past instances, the stock price increased further within the following month. The odds of a continued upward trend are 68%.
The Momentum Indicator moved above the 0 level on October 13, 2026. You may want to consider a long position or call options on PHG as a result. In 46 of 79 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 58%.
The Moving Average Convergence Divergence (MACD) for PHG just turned positive on October 08, 2026. Looking at past instances where PHG's MACD turned positive, the stock continued to rise in 28 of 48 cases over the following month. The odds of a continued upward trend are 58%.
Following a +3.54% 3-day Advance, the price is estimated to grow further. Considering data from situations where PHG advanced for three days, in 203 of 312 cases, the price rose further within the following month. The odds of a continued upward trend are 65%.
The RSI Indicator has been in the overbought zone for 2 days. Expect a price pull-back in the near future.
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 7 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where PHG declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 65%.
PHG broke above its upper Bollinger Band on October 22, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for PHG entered a downward trend on October 14, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The Tickeron Valuation Rating of 5 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.240) is normal, around the industry mean (2.874). P/E Ratio (22.419) is within average values for comparable stocks, (2.324). Projected Growth (PEG Ratio) (0.768) is also within normal values, averaging (11.052). PHG's Dividend Yield (0.154) is considerably higher than the industry average of (0.009). P/S Ratio (1.175) is also within normal values, averaging (40.124).
The Tickeron Price Growth Rating for this company is 49 (best 1 - 100 worst), indicating steady price growth. PHG’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 69 (best 1 - 100 worst), indicating slightly better than average sales and a considerably profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is 96 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. PHG’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.
BAX | PHG | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 10 | 28 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 96 Overvalued | 5 Undervalued | |
PROFIT vs RISK RATING 1..100 | 100 | 100 | |
SMR RATING 1..100 | 94 | 69 | |
PRICE GROWTH RATING 1..100 | 16 | 49 | |
P/E GROWTH RATING 1..100 | 56 | 96 | |
SEASONALITY SCORE 1..100 | 85 | n/a |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
PHG's Valuation (5) in the Electronic Production Equipment industry is significantly better than the same rating for BAX (96) in the Medical Specialties industry. This means that PHG’s stock grew significantly faster than BAX’s over the last 12 months.
PHG's Profit vs Risk Rating (100) in the Electronic Production Equipment industry is in the same range as BAX (100) in the Medical Specialties industry. This means that PHG’s stock grew similarly to BAX’s over the last 12 months.
PHG's SMR Rating (69) in the Electronic Production Equipment industry is in the same range as BAX (94) in the Medical Specialties industry. This means that PHG’s stock grew similarly to BAX’s over the last 12 months.
BAX's Price Growth Rating (16) in the Medical Specialties industry is somewhat better than the same rating for PHG (49) in the Electronic Production Equipment industry. This means that BAX’s stock grew somewhat faster than PHG’s over the last 12 months.
BAX's P/E Growth Rating (56) in the Medical Specialties industry is somewhat better than the same rating for PHG (96) in the Electronic Production Equipment industry. This means that BAX’s stock grew somewhat faster than PHG’s over the last 12 months.
| BAX | PHG | |
|---|---|---|
| RSI ODDS (%) | 1 day ago 55% | 1 day ago 55% |
| Stochastic ODDS (%) | 1 day ago 60% | 1 day ago 63% |
| Momentum ODDS (%) | 1 day ago 56% | 1 day ago 58% |
| MACD ODDS (%) | 1 day ago 47% | 1 day ago 58% |
| TrendWeek ODDS (%) | 1 day ago 68% | 1 day ago 60% |
| TrendMonth ODDS (%) | 1 day ago 64% | 1 day ago 56% |
| Advances ODDS (%) | 1 day ago 58% | 1 day ago 65% |
| Declines ODDS (%) | 3 days ago 68% | 22 days ago 65% |
| BollingerBands ODDS (%) | 1 day ago 70% | 1 day ago 67% |
| Aroon ODDS (%) | 1 day ago 68% | 1 day ago 59% |
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
BAX’s FA Score shows that 1 FA rating(s) are green while PHG’s FA Score has 1 green FA rating(s).
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
BAX’s TA Score shows that 4 TA indicator(s) are bullish while PHG’s TA Score has 4 bullish TA indicator(s).
BAX (@Pharmaceuticals: Other) experienced а -0.40% price change this week, while PHG (@Medical/Nursing Services) price change was +4.92% for the same time period.
The average weekly price growth across all stocks in the @Pharmaceuticals: Other industry was +0.74%. For the same industry, the average monthly price growth was -3.62%, and the average quarterly price growth was +9.09%.
The average weekly price growth across all stocks in the @Medical/Nursing Services industry was -1.62%. For the same industry, the average monthly price growth was -10.72%, and the average quarterly price growth was -10.29%.
BAX is expected to report earnings on Oct 29, 2026.
PHG is expected to report earnings on Nov 03, 2026.
Pharmaceuticals (Other) comprise companies that are involved in the discovery, development or manufacturing of therapeutic and preventative medicines. They often collaborate with or acquire other pharmaceutical/healthcare firms. Examples of companies in this segment include Bausch Health Companies Inc., Icon Plc and Perrigo Company Plc.
@Medical/Nursing Services (-1.62% weekly)The medical/nursing services includes companies that provide medical-related services such as ambulance services, dialysis centers, respiratory therapy, blood testing and rehabilitation services. DaVita Inc., Chemed Corporation and Guardant Health, Inc. are examples of companies in this industry.
A.I.dvisor indicates that over the last year, BAX has been loosely correlated with LUNG. These tickers have moved in lockstep 53% of the time. This A.I.-generated data suggests there is some statistical probability that if BAX jumps, then LUNG could also see price increases.
| Ticker / NAME | Correlation To BAX | 1D Price Change % | ||
|---|---|---|---|---|
| BAX | 100% | +3.85% | ||
| LUNG - BAX | 53% Loosely correlated | +2.73% | ||
| ICUI - BAX | 52% Loosely correlated | +4.66% | ||
| STE - BAX | 51% Loosely correlated | +4.85% | ||
| SYK - BAX | 51% Loosely correlated | +3.19% | ||
| BDX - BAX | 49% Loosely correlated | +3.13% | ||
More | ||||
A.I.dvisor indicates that over the last year, PHG has been loosely correlated with GEHC. These tickers have moved in lockstep 53% of the time. This A.I.-generated data suggests there is some statistical probability that if PHG jumps, then GEHC could also see price increases.
| Ticker / NAME | Correlation To PHG | 1D Price Change % | ||
|---|---|---|---|---|
| PHG | 100% | +2.63% | ||
| GEHC - PHG | 53% Loosely correlated | +3.49% | ||
| ALC - PHG | 49% Loosely correlated | +4.75% | ||
| STE - PHG | 44% Loosely correlated | +4.85% | ||
| IRMD - PHG | 42% Loosely correlated | -0.19% | ||
| BAX - PHG | 40% Loosely correlated | +3.85% | ||
More | ||||